Moderna 4 jun 2026 Heated LNP litigation puts Moderna and Acuitas in the spotlight - Life Sciences Intellectual Property Review
Moderna 2 jun 2026 ASCO: Moderna’s mRNA-based melanoma vaccine shows ‘encouraging’ 5-year survival - BioSpace
Moderna 1 jun 2026 Biopharma bites: Setbacks for Fulcrum, Praxis, while Shionogi, Moderna make infectious disease strides - FirstWord Pharma
Moderna 1 jun 2026 Moderna and CEPI expand collab to include Bundibugyo ebolavirus vaccine - The Pharma Letter
Moderna 21 may 2026 Forget Moderna: This Biotech Juggernaut Is a Way Better Buy Right Now - Yahoo Finance
Moderna 20 may 2026 ROIV: Strong clinical progress and a $2.25B Moderna settlement drive robust financial position - TradingView
Moderna 14 may 2026 Salesforce (CRM), Moderna Partner to Unify Global Operations via Agentforce Life Sciences - Yahoo Finance
Moderna 13 may 2026 Moderna Is a Money-Losing Vaccine Maker. It’s Also the Ultimate Stock Hedge. - Barron's
Moderna 11 may 2026 Moderna Stock Loses Steam. Hantavirus Trade Fizzles as Officials Dismiss Pandemic Risk. - Barron's
Moderna 11 may 2026 Moderna’s stock has rallied on hantavirus research that is ‘early-stage’ in nature - MarketWatch
Moderna 11 may 2026 Biotech Stocks Rally on Hantavirus Fears: Is the Surge Overdone? - The Motley Fool
Moderna 11 may 2026 Moderna (MRNA) Stock Jumps After Hantavirus Outbreak Sparks Biotech Rally - CoinCentral
Moderna 11 may 2026 Hantavirus cases spark brief surge in pharma and biotech stocks — here’s why trading is so volatile - CNBC
Moderna 11 may 2026 Moderna shares spike after pre-outbreak hantavirus vaccine work revealed - medwatch.com
Moderna 8 may 2026 Moderna Works on Hantavirus: Reports Claim the Biotech Giant Has Started Early-Stage Research of the Jab - International Business Times UK